.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02A_HormonesAndRelatedAgents.L02AA02_PolyestradiolPhosphate.PolyestradiolPhosphate .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02A_HormonesAndRelatedAgents.L02AA02_PolyestradiolPhosphate.PolyestradiolPhosphate| name: | PolyestradiolPhosphate |
| ATC code: | L02AA02 | route: | intramuscular |
| n-compartments | 1 |
Polyestradiol phosphate (PEP) is a long-acting parenteral estrogen used primarily in the treatment of advanced prostate cancer in men. It acts as an estrogen receptor agonist, exerting anti-androgenic effects by suppressing testosterone production. Its clinical use has declined with the availability of more modern therapies, but may still be found in some regions.
Pharmacokinetic parameters estimated for adult male patients with advanced prostate cancer, following intramuscular administration.